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THE PEARRL REVIEWS - innovative drug development strategies tailored to facilitate earlier access 
to new oral medicines. 
Guest Editors: Brendan T. Griffin and Jennifer B. Dressman 
Pharmaceutical Education and Research with Regulatory Links (PEARRL) is an EU-sponsored 
partnership consisting of contributors from the pharmaceutical industry, academia and regulatory 
agencies, with the collective goal of developing innovative drug development strategies and 
regulatory tools tailored to facilitate earlier access to medicines (www.pearrl.eu ). 
A major bottleneck to development of new oral medicines is the poor solubility of many drug 
candidates. The need to develop bioenabling formulations for poorly soluble drug candidates which 
offer new and clear therapeutic benefits is particularly urgent.  The PEARRL consortium is addressing 
this formulation issue by developing innovative bio-enabling formulation technologies to develop 
the new drugs, and by providing guides (“scorecards”) for formulators to use in selecting the most 
suitable bio-enabling formulation on the basis of the drug properties. Additionally, PEARRL is 
providing a series of in vitro and in vivo biopharmaceutics tools which can be used in conjunction 
with PBPK models tailored for specific patient populations to predict in vivo performance of the bio-
enabling formulations.  
This special issue of the Journal of Pharmacy and Pharmacology hosts a collection of eleven review 
articles that showcase the research topics that are the focus of the PEARRL consortium. The 
objective of these review articles is to provide an up-to-date review on the current status of the 
target areas of research and to highlight approaches which can be used to streamline oral drug 
product development.   
The first three articles address tools to facilitate the design of bio-enabling oral formulations for 
poorly water-soluble drugs. The review article by Jankovic et al. provides a detailed overview of the 
methods employed to calculate solubility parameters, ranging from traditional to modern 
approaches, and highlights how solubility parameters can be used to guide the design of bioenabling 
formulations for a given drug. The Ditzinger et al. review focuses on descriptors of lipophilicity and 
hydrophobicity as tools for guiding on oral drug product development with an emphasis on bio-
enabling formulation technologies.  In addition to these contributions, Price et al. address 
formulations intended to result in supersaturated concentrations of drug in the GI tract, providing 
new insights on selection of an optimal precipitation inhibitor using advanced analytical techniques. 
Rounding out the section on formulation development, the article by O’Shea et al. focuses on 
formulation approaches to overcome variable food effect oral bioavailability.   
The second set of reviews focuses on bio-relevant in vitro approaches for assessing oral drug 
formulations.  The article by O’Dwyer et al. provides a detailed overview of current in vitro methods 
for evaluating the potential risk of drug precipitation, with an emphasis on techniques that allow 
rapid screening of prototype formulations under simulated fasted state intestinal conditions. 
Subsequently, Pentafragka et al. provide a detailed overview of the luminal environment under fed 
state conditions, and highlight the need for improved in vitro methods for evaluating drug product 
performance in the fed state.  The review by Henze et al. discusses in depth the value of pigs as a 
preclinical model for predicting oral bioavailability in humans, and highlights the need for species-
specific physiologically based pharmacokinetic (PBPK) models to better link results from pre-clinical 
models to clinical studies in humans.  The fourth review in the area of biopharmaceutical tools, by 
Guimarães M. et al., addresses the need for specialised bio-relevant tools to evaluate oral 
formulation performance in paediatric patients, and recommends coupling in vitro and in silico 
methods as an approach to improve in vivo predictions. 
The final group of review articles explores in more detail approaches to ‘link the lab to the patient’ 
using PBPK modelling, with a view to expediting clinical development. The review by Litou et al. calls 
out the need for greater recognition of the impact gastrointestinal medicines can have on intestinal 
conditions, which can lead to altered pharmacokinetics of co-administered drugs, and how to predict 
the in vivo impact of these drug-drug interactions. Analogously, Effinger et al. review the 
physiological changes that occur in patients with gastrointestinal disease which can result in altered 
drug absorption. The authors provide examples of the use of in silico models tailored specifically for 
the gastrointestinal conditions in these special patient populations as a means to improve their drug 
therapy.  Last but not least, Loisios-Konstantinidis et al. provide an overview of 
pharmacokinetic/pharmacodynamic (PK/PD) models, focusing on drug-specific models to improve 
predictability of therapeutic equivalence between formulations and to highlight their additive value 
in regulatory decision-making.  
Together, the PEARRL reviews describe the state of the art and identifies the key issues that will 
need to be addressed to bring oral dosage form development to the next level, and contribute 
substantially towards the much-needed integration of disciplines in the field of bio-enabling 
formulation design, biorelevant testing and patient-tailored PBPK approaches. 
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